Bausch & Lomb Corp (BLCO)
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.
- Symbol
- BLCO
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Market cap
- $6.09B
- 52 week range
- 13.77 - 18.92
Valuation
- Share price
- $17.05 (close of 2026-09-23)
- P/E (TTM)
- -35.52x
- Price to book
- 0.94x
- Price to free cash flow
- 44.44x
- Enterprise value
- $10.84B
- Book value per share
- $18.05
Price performance
| Period | Change |
|---|
| 1 day | +1.49% |
| 5 days | -1.04% |
| 1 month | -1.10% |
| 3 months | +11.88% |
| 6 months | +7.64% |
| Year to date | -0.18% |
| 1 year | +13.06% |
| 3 years | 0.00% |
| All time | -14.75% |
Profitability and growth
- Return on equity
- -5.52%
- Return on invested capital
- 0.70%
- Return on assets
- -2.57%
- Return on capital employed
- 0.93%
- Gross margin
- 46.01%
- Net margin
- -7.06%
- EBITDA margin
- 10.47%
- Revenue growth
- 6.47%
- Net income growth
- -13.56%
- Free cash flow growth
- -11.86%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 2.25%
- Current ratio
- 1.55x
- Net debt to EBITDA
- 6.46x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $5.10B
- Cost of revenue
- $2.75B
- Gross profit
- $2.35B
- EBITDA
- $534.00M
- Net income
- $-360.00M
- Earnings per share
- $-1.02
- Shares outstanding
- 353.80M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|
| 2025-12-31 | $5.10B | $2.35B | $-360.00M | $-1.02 |
| 2024-12-31 | $4.79B | $2.24B | $-317.00M | $-0.90 |
| 2023-12-31 | $4.15B | $1.87B | $-260.00M | $-0.74 |
| 2022-12-31 | $3.77B | $1.69B | $6.00M | $0.02 |
| 2021-12-31 | $3.77B | $1.72B | $182.00M | $0.52 |
| 2020-12-31 | $3.41B | $1.51B | $-18.00M | $-0.05 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|
| 2025-12-31 | 46.01% | -7.06% | -5.52% | 0.70% |
| 2024-12-31 | 46.84% | -6.62% | -4.84% | 0.83% |
| 2023-12-31 | 45.01% | -6.27% | -3.76% | 0.58% |
| 2022-12-31 | 44.72% | 0.16% | 0.08% | 1.62% |
| 2021-12-31 | 45.63% | 4.83% | 1.94% | 2.18% |
| 2020-12-31 | 44.34% | -0.53% | -0.18% | 1.33% |
Cash and debt by year
| Period end | Cash | Debt |
|---|
| 2025-12-31 | $383.00M | $5.02B |
| 2024-12-31 | $305.00M | $4.74B |
| 2023-12-31 | $331.00M | $4.53B |
| 2022-12-31 | $354.00M | $2.41B |
| 2021-12-31 | $174.00M | - |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2025-12-31 | $-66.00M | $149.00M |
| 2024-12-31 | $-59.00M | $92.00M |
| 2023-12-31 | $-198.00M | $74.00M |
| 2022-12-31 | $170.00M | $62.00M |
| 2021-12-31 | $680.00M | $62.00M |
| 2020-12-31 | $269.00M | $50.00M |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-04
- Consensus EPS estimate
- $0.21
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-07-29 | Jun/2026 | $0.16 |
| 2026-04-29 | - | - |
| 2026-02-18 | - | - |
| 2025-10-29 | - | - |
| 2025-07-30 | - | - |
| 2025-05-29 | - | - |
| 2025-04-30 | - | - |
| 2025-02-19 | - | - |
Filings and sources
- Company website
- bausch.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Intuitive Surgical Inc (ISRG) · Becton Dickinson & Co (BDX) · ResMed Inc (RMD) · West Pharmaceutical Services Inc (WST) · Baxter International Inc (BAX) · Align Technology Inc (ALGN) · Cooper Companies, Inc. (COO) · Vertex Pharmaceuticals Inc (VRTX)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades